Skip to main content

Advertisement

Log in

A Quantitative Disintegration Method for Polymeric Films

  • Original Article
  • Published:
Journal of Pharmaceutical Innovation Aims and scope Submit manuscript

Abstract

Purpose

Current in vitro disintegration methods for polymeric films are qualitative and introduce significant user bias. The goal of these studies is to develop a novel, quantitative disintegration technique which can be used to characterize polymeric films in vitro.

Methods

A method was developed using a Texture Analyzer instrument to evaluate film disintegration. Solvent-casted, clinically advanced, anti-HIV, vaginal films as well as marketed vaginal films were used throughout these studies. Method development followed a quality by design (QbD) process and was used to evaluate film products.

Results

The current method developed provided reproducible, quantitative disintegration times for the commercially available vaginal contraceptive film (57.88 ± 5.98 s). It distinguished between two clinically advanced antiretroviral containing films based on disintegration time (p value < 0.001): the tenofovir film (41.28 ± 3.35 s) and the dapivirine film (88.36 ± 10.61 s). This method could also distinguish between tenofovir and dapivirine films which had been altered in terms of volume (p < 0.0001) and formulation (p < 0.0001) based on disintegration time.

Conclusions

This method can be applied for pharmaceutical films for ranging indications as part of vigorous in vitro characterization. Parameters of the test can be altered based on site of application or indication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: a new approach to oral drug delivery system. Int J Pharm Investig. 2013;3(2):67–76. https://doi.org/10.4103/2230-973X.114897.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Ferguson LM, Rohan LC. The importance of the vaginal delivery route for antiretrovirals in HIV prevention. Ther Deliv. 2011;2(12):1535–50. https://doi.org/10.4155/tde.11.126.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Bunge KE, Dezzutti CS, Rohan LC, Hendrix CW, Marzinke MA, Richardson-Harman N, et al. A phase 1 trial to assess the safety, acceptability, pharmacokinetics, and pharmacodynamics of a novel dapivirine vaginal film. JAIDS J Acquir Immune Defic Syndr. 2016;71(5):498–505.

    Article  CAS  Google Scholar 

  4. Robinson JA, Marzinke MA, Bakshi RP, Fuchs EJ, Radebaugh CL, Aung W, et al. Comparison of dapivirine vaginal gel and film formulation pharmacokinetics and pharmacodynamics (FAME 02B). AIDS Res Hum Retrovir. 2017;33(4):339–46. https://doi.org/10.1089/AID.2016.0040.

    Article  CAS  PubMed  Google Scholar 

  5. Bunge K, Dezzutti C, Macio I, Hendrix C, Lisa C, Rohan L, editors. FAME-02: a phase I trial to assess safety, PK, and PD of gel and film formulations of dapivirine. Conference on Retroviruses and Opportunistic Infections (CROI); 2014.

  6. Bunge KE, Editor. Phase I trial to assess safety, PK, and PD of film and gel formulations of tenofovir. Conference on retroviruses and opportunistic infections (CROI); 2016; Boston, Massachusetts.

  7. Fernández-Romero JA, Deal C, Herold BC, Schiller J, Patton D, Zydowsky T, et al. Multipurpose prevention technologies: the future of HIV and STI protection. Trends Microbiol. 2015;23(7):429–36.

    Article  Google Scholar 

  8. Anderson D, J. Monoclonal antibody-based multipurpose microbicides. National Institute of Allergy and Infectious Diseases. 2011. https://projectreporter.nih.gov/project_info_description.cfm?aid=8209659&icde=0. Accessed 2 March 2018.

  9. Akil A, Parniak MA, Dezzuitti CS, Moncla BJ, Cost MR, Li M, et al. Development and characterization of a vaginal film containing dapivirine, a non- nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. Drug Deliv Transl Res. 2011;1(3):209–22. https://doi.org/10.1007/s13346-011-0022-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Arya A, Chandra A, Sharma V, Pathak K. Fast dissolving oral films: an innovative drug delivery system and dosage form. Int J Chem Tech Res. 2010;2(1):576–83.

    CAS  Google Scholar 

  11. Kalyan S, Bansal M. Recent trends in the development of oral dissolving film. Int J PharmTech Res. 2012;4(2):725–33.

    CAS  Google Scholar 

  12. Akil A, Agashe H, Dezzutti CS, Moncla BJ, Hillier SL, Devlin B, et al. Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV prevention. Pharm Res. 2015;32(2):458–68.

    Article  CAS  Google Scholar 

  13. Ham AS, Rohan LC, Boczar A, Yang L. K WB, Buckheit RW, Jr. Vaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection. Pharm Res. 2012;29(7):1897–907. https://doi.org/10.1007/s11095-012-0715-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Administration UFD. Guidance for industry orally disintegrating tablets. Silver Spring, MD: Center for Drug Evaluation and Research (CDER), US Dept of Health and Human Services. 2008.

  15. Convention TUSP. The United States Pharmacopeia convention. Chapter <701> disintegration. Rockville: The United States Pharmacopeia Convention; 2009.

    Google Scholar 

  16. Bhyan B, Jangra S, Kaur M, Singh H. Orally fast dissolving films: innovations in formulation and technology. Int J Pharm Sci Rev Res. 2011;9(2):9–15.

    Google Scholar 

  17. Low A, Kok SL, Khong Y, Chan SY, Gokhale R. Pharmaceutics, drug delivery and pharmaceutical technology: a new test unit for disintegration end-point determination of orodispersible films. Journal of pharmaceutical sciences. 2015;104(11):3893–903. doi:doi:https://doi.org/10.1002/jps.24609.

  18. Garsuch V, Breitkreutz J. Comparative investigations on different polymers for the preparation of fast-dissolving oral films. J Pharm Pharmacol. 2010;62(4):539–45. https://doi.org/10.1211/jpp.62.04.0018.

    Article  CAS  PubMed  Google Scholar 

  19. Preis M, Woertz C, Schneider K, Kukawka J, Broscheit J, Roewer N, et al. Design and evaluation of bilayered buccal film preparations for local administration of lidocaine hydrochloride. Eur J Pharm Biopharm. 2014;86(3):552–61.

    Article  CAS  Google Scholar 

  20. Irfan M, Rabel S, Bukhtar Q, Qadir MI, Jabeen F, Khan A. Orally disintegrating films: a modern expansion in drug delivery system. Saudi Pharm J. 2016;24(5):537–46. https://doi.org/10.1016/j.jsps.2015.02.024.

    Article  PubMed  Google Scholar 

  21. Preis M, Gronkowsky D, Grytzan D, Breitkreutz J. Comparative study on novel test systems to determine disintegration time of orodispersible films. J Pharm Pharmacol. 2014;66(8):1102–11. https://doi.org/10.1111/jphp.12246.

    Article  CAS  PubMed  Google Scholar 

  22. Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotech. 2009;27(1):26–34.

    Article  CAS  Google Scholar 

  23. Winkle H, editor. Implementing quality by design. PDA/FDA Joint Regulatory Conference; 2007.

  24. Borman P, Chatfield M, Nethercote P, Thompson D, Truman K. The application of quality by design to analytical methods. Pharm Technol. 2007;31(12):142–52.

    Google Scholar 

  25. Puertollano M, Cartwright T, Aylott M, Kaye N. Assessing an analytical method for the dissolution profile of an extended-release tablet in accordance with QbD. Tablets Capsules. 2009;7(1):30–9.

    Google Scholar 

  26. Robinson JA, Marzinke MA, Fuchs EJ, Bakshi RP, Spiegel HML, Coleman JS, et al. Comparison of the pharmacokinetics and pharmacodynamics of single-dose tenofovir vaginal film and gel formulation (Fame-05). J Acquir Immune Defic Syndr. 2017:1. https://doi.org/10.1097/qai.0000000000001587.

  27. Kieweg SL, Katz DF. Interpreting properties of microbicide drug delivery gels: analyzing deployment kinetics due to squeezing. J Pharm Sci. 2007;96(4):835–50.

    Article  CAS  Google Scholar 

  28. Owen DH, Katz DF. A vaginal fluid simulant. Contraception. 1999;59(2):91–5.

    Article  CAS  Google Scholar 

  29. Ham AS, Rohan LC, Boczar A, Yang L, Buckheit KW, Buckheit RW Jr. Vaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection. Pharm Res. 2012;29(7):1897–907.

    Article  CAS  Google Scholar 

  30. Machado RM, Palmeira-De-Oliveira A, Martinez-De-Oliveira J, Palmeira-De-Oliveira R. Vaginal films for drug delivery. J Pharm Sci. 2013;102(7):2069–81. https://doi.org/10.1002/jps.23577.

    Article  CAS  PubMed  Google Scholar 

  31. Grammen C, Van den Mooter G, Appeltans B, Michiels J, Crucitti T, Ariën KK et al. Development and characterization of a solid dispersion film for the vaginal application of the anti-HIV microbicide UAMC01398. Int J pharma. 2014;475(1–2):5–44. doi:doi:https://doi.org/10.1016/j.ijpharm.2014.08.054.

Download references

Acknowledgements

The current work was funded through the National Institute of Allergy and Infectious Diseases (grant numbers 5U19AI120249, 5U19AI082639) and the Bill & Melinda Gates Foundation. Tenofovir was graciously provided by CONRAD (Arlington, VA, USA), and dapivirine was graciously provided by the International Partnership for Microbicides (IPM, Silver Spring, MD, USA). We would like to acknowledge Jeanne Held of Texture Technologies for the guidance in the establishment of this method. We would also like to acknowledge Sravan Patel for his help in the preparation of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lisa C. Rohan.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grab, S., Rohan, L.C. A Quantitative Disintegration Method for Polymeric Films. J Pharm Innov 13, 321–329 (2018). https://doi.org/10.1007/s12247-018-9325-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12247-018-9325-1

Keywords

Navigation